Latanotears (Latanoprost)

Latanoprost mimics prostaglandin F2α and binds to FP receptors in the ciliary body. This activation remodels extracellular matrix proteins, increasing uveoscleral outflow of aqueous humor, which leads to a sustained reduction in intraocular pressure.

The dosing regimen is determined by the prescribing ophthalmologist. Typically, one drop is instilled once daily in the affected eye(s), often in the evening, but the exact schedule should follow the clinician’s instructions.

Latanoprost is classified as pregnancy category C, meaning it should be used only if the potential benefit outweighs any potential risk to the fetus. Safety during breastfeeding has not been established, so caution and medical advice are recommended.

To request Latanotears, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Compared with beta‑blocker eye drops, latanoprost often achieves greater intraocular pressure reduction with once‑daily dosing and a distinct side‑effect profile, such as increased eyelash growth. It is considered a first‑line therapy among prostaglandin analogs for many patients.

Latanotears should be stored below 25 °C in its original container, protected from light and moisture. Do not freeze the product, keep it out of reach of children, and discard any solution that appears discolored or contaminated.

Instill one drop into the conjunctival sac of the prescribed eye(s) using aseptic technique. Avoid touching the dropper tip to the eye or eyelid, close the eye gently for a few minutes, and refrain from blinking excessively immediately after application.

Rare but serious adverse events include uveitis, macular edema, severe ocular inflammation, and marked hypotony (excessive pressure drop) that can threaten vision. Patients should seek immediate medical attention if they experience sudden vision loss, eye pain or intense redness.

Individuals with known hypersensitivity to latanoprost or any component of the formulation, those with active ocular infections or inflammation, and patients who have recently undergone ocular surgery should avoid using Latanotears unless directed otherwise by a qualified eye‑care professional.